

REMARKS

Claim Amendments

Claims 1-25 are pending in this application. With the present submission, claims 2, 12, 14, 17, 18, 19, and 21 have been cancelled without prejudice or disclaimer. Claims 1, 3, 6, and 16 have been amended.

Claim 1 has been amended to recite that the assay system comprises cultured cells that express a CSNK1G polypeptide or nucleic acid. Support for the amendment can be found throughout the specification and in original claim 2.

Claim 3 has been amended merely to correct the dependency.

Claim 6 has been amended merely to delete reference to the non-elected inventions.

Claim 16 has been amended to recite that the second assay system comprises cultured cells that express a CSNK1G polypeptide or nucleic acid, wherein the second assay system can detect an agent-biased change in the p21 pathway. Support for the amendment can be found throughout the specification and in original claim 16.

The claim amendments are made solely in an effort to advance prosecution and are made without prejudice or disclaimer, without intent to acquiesce in any rejection of record, and without intent to abandon any previously claimed subject matter. Additionally, these amendments and cancellation are not and should not be construed as admissions regarding the patentability of the claimed or canceled subject matter. Applicants reserve the right to pursue the subject matter of previously presented claims in this or in any other appropriate patent application. No new matter has been added by way of these amendments. Accordingly, Applicants respectfully request the entry of the amendments presented.

Non-Compliant Amendment

Claims 1-3, 6, 16, and 17 were originally objected to for allegedly reciting non-elected subject matter. Applicants amended the claims to address the objection in the Amendment and Response to Office Action mailed on January 14, 2008.

The Office subsequently issued a Notice of Non-Compliant Amendment alleging that the claims as amended do not encompass the elected subject matter, drawn to a method for identifying a modulator using a cell proliferation assay system, because the specification allegedly fails to disclose a method for assaying cell proliferation wherein CSNK1G expression or activity is used as an indicator of proliferation.

In response, Applicants submit herewith a corrected “Amendments to the Claims” section. Applicants note that claim 2 and claim 17 have been canceled herein without prejudice. Claims 1 and 16 have been amended herein to address the Office’s allegations.

Applicants believe that the response to the Notice of Non-Compliant Amendment is complete with the submission of the corrected “Amendments to the Claims” section.

CONCLUSION

In view of the above remarks, the application is considered to be in good and proper form for allowance and the Examiner is respectfully requested to pass this application to issue.

Respectfully submitted,

Date: September 29, 2008

/Anita J. Terpstra/
Anita J. Terpstra
Registration No. 47,132